abstract |
The disclosure provides methods, biomarkers, and kits for determining the prognosis of Zika virus infection in relation to severity of symptoms resulting from effects of the Zika virus infection on bone metabolism, such as arthralgia, osteoporosis, and craniosynostosis. The disclosure further provides treatments for Zika virus infection, in particular for treating arthralgia, osteoporosis, and craniosynostosis. |